Fertilis, an Australian medtech company, has developed the prototype of an innovative device, microICSI, aimed at refining the IVF process. A recent study published in the Journal of Assisted Reproduction and Genetics study, titled “A micro-fabricated device (microICSI) improves porcine blastocyst development and procedural efficiency for both porcine intracytoplasmic sperm injection and human microinjection,” now underscores the device’s effectiveness in improving embryo development and streamlining the IVF procedure.
MicroICSI is meticulously designed to lessen the stress on the oocyte during injection, a critical phase in IVF. It positions oocytes in microfabricated wells, enhancing stability and precision during the procedure. The study’s results are promising, showing that the use of microICSI in a porcine model notably increased the blastocyst development rate compared to the conventional method. While the growth and division of the embryos were consistent across both methods, microICSI notably improved the efficiency of the procedure by reducing the time and manual adjustments required.
The research also included an initial exploration with human oocytes, suggesting the potential applicability and advantages of microICSI in human IVF treatments. This innovation by Fertilis marks a significant stride in the field of fertility treatments, offering a more refined approach to IVF. The development of MicroICSI aligns with Fertilis’s commitment to advancing fertility outcomes through technological innovation, signifying a forward leap in the domain of assisted reproductive technology.
